Month: August 2025

HONG KONG, Aug. 19, 2025 (GLOBE NEWSWIRE) — via IBN — SOLOWIN HOLDINGS (NASDAQ: SWIN) (“Solowin” or the “Company”), a leading financial services firm providing comprehensive solutions across traditional and digital assets, today announced the entrance of an equity purchase agreement of its 19% equity acquisition in GPL Remittance Pte. Ltd., (“GPL”), a Singapore-based cross-border payment institution. GPL holds a Major Payment Institution (MPI) license issued by the Monetary Authority of Singapore (MAS), and has over 30 years of global operational expertise. This transaction marks a strategic enhancement to Solowin’s digital payment infrastructure.  Peter Lok, Chief Executive Officer of Solowin, stated: “This investment will strengthen our licensed payment channels in the region, serving not only as the compliance baseline...

Acquisition Poised to Accelerate Life-Saving Interventions, Combining Academic Excellence with Real-World Innovation to Address Global Addiction Crises and Unlock Multi-Billion Market Opportunities VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC: BLEG), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a groundbreaking strategic partnership between its wholly-owned subsidiary, Bio-Legacy Evaluative Group, and McMaster University, one of the world’s top medical universities renowned for its influential research in addiction medicine, clinical trials, and guideline development at state, provincial, national, and international levels. This collaboration will focus on evaluating Bio-Legacy Evaluative Group’s...

Please see below information about transactions made under the third tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO). Date on which the buy-back tranche was announced: 23 July 2025.The duration of the buy-back tranche: 24 July to no later than 27 October 2025. Further information on the tranche can be found in the stock market announcement on its commencement dated 23 July 2025, available here: https://newsweb.oslobors.no/message/651645 From 11 August to 14 August 2025, Equinor ASA has purchased a total of 1,073,277 own shares at an average price of NOK 249.2350 per share. Overview of transactions:Date Trading venue Aggregated daily volume (number of shares) Daily weighted average share price (NOK) Total daily transaction value (NOK)         11 August OSE 270,000 249.3579 67,326,633.00  CEUX        TQEX               12...

SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that the advisors of Zarra Wealth Management have joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) platform. They reported serving approximately $270 million in advisory, brokerage and retirement plan assets* and join LPL from Ameriprise. Based on Long Island, in Westbury, NY, the team consists of Christopher Zarra, CFP®, CHFC®, CFS®, James Kelly CFP®, APMA™ and Michele Welch, CFP®. They bring 48 years of collective financial industry experience focusing on families, pre-retiree and retiree clients. The team in particular prides itself on achieving the rigorous CFP® designation and providing the utmost in fiduciary guidance to their clients. “We’re often introduced to our clients’ family members because of the high-touch,...

90-day trial measuring change in general fatigue in chronic babesiosis patients Enrollment expected to commence Q4 2025 and to be completed by Q2 2026 Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosis No FDA-approved treatment exists for chronic babesiosis, a debilitating illnessWASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today it has signed a clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York City as the central site for a Phase II clinical study of tafenoquine in treating chronic babesiosis. For the...